PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1385661
PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1385661
The global revenue from the Peripheral Stent Implants Market was approximately US$ 3.9 Billion in 2024. The market is anticipated to reach a valuation of approximately US$ 7.1 Billion by the end of 2031.
Rising Patient Base and Geriatric Population: The prevalence of peripheral artery disease (PAD) has been on the rise, driven by factors such as smoking, diabetes, and hypercholesterolemia, which are associated with cardiovascular diseases (CVD). This has created a growing patient base for peripheral stent implants.
Favorable Reimbursement Policies: Favorable reimbursement policies for outpatient surgery have contributed to the market's growth. An increase in outpatient cases, particularly in developing nations, has further boosted demand for peripheral vascular devices.
Stringent Regulations: The production and use of peripheral stent implants are subject to strict regulations and lengthy approval processes by organizations like the FDA and CE Mark, which can limit market growth.
Product Recalls: Instances of product recalls due to adverse health consequences, such as bleeding risks and strokes, have affected the market. These recalls can erode consumer confidence and hinder market expansion.
Healthcare Costs and Public Awareness: While peripheral stent implants are more affordable than surgical procedures, hospitalization costs remain significant. Increasing public awareness of asymptomatic PAD and its early detection is essential, particularly in resource-limited nations.
United States: The U.S. holds a dominant market share due to the high prevalence of PAD driven by factors like smoking, sedentary lifestyles, and a large geriatric population. Availability of drug-eluting stents and favorable medical reimbursement policies contribute to market growth.
Germany: Germany is a lucrative market driven by product innovation, investment in advanced stents, and a rising prevalence of obesity. The market benefits from an increase in minimally invasive surgeries and percutaneous coronary intervention (PCI) procedures.
China: China plays a significant role in manufacturing stent grafts and exporting products to neighboring countries. Advanced products, a high geriatric population, and product exports contribute to its prominence in the market.
Key players are focusing on expanding their sales and marketing investments globally, with a direct sales force, clinical specialists, distributors, and strategic partnerships. Collaboration with leading distributors and product development with groundbreaking advancements are central to their strategies.